Anti-inflammatory role of sesamin in STZ induced mice model of diabetic retinopathy

Saif Ahmad, Nehal M. ElSherbiny, Mohammad Sarwar Jamal, Faisal A. Alzahrani, Rizwanul Haque, Raziuddin Khan, Syed Kashif Zaidi, Mohammed H. AlQahtani, Gregory I Liou, Kanchan Bhatia

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Diabetic retinopathy (DR) is the common cause of diabetic vascular complications that leads to the blindness in the working age population throughout the world. Free radicals mediated oxidative stress and inflammation play a significant role in pathophysiology of DR. To find a new and safe drug to treat DR is still challenging and for that purpose the natural compounds may be therapeutic agents. Here we show that sesamin (SES) which is the main components of sesame seed and its oil, and has been reported as potent antioxidant and neuroprotective, could be a therapeutic agent in DR. In the present study, we investigated protective effect of SES in Streptozotocin (STZ) induced DR in mice. The mice were divided into three groups (Control, DR and DR+SES) for the study. After two weeks post-diabetic establishment, mice were treated with SES (30 mg/kg BW, i.p, alternate day) for four weeks. Mice body weight and blood glucose level were measured from each group. The microglial activation of retina was determined by immunohistochemistry analysis by using Iba-1 as a microglia marker. Retinal mRNA levels of Iba-1, tumor necrosis factor-α (TNF-α), inducible nitric oxide synthase (iNOS) and Intercellular Adhesion Molecule 1 (ICAM-1) were examined by qRT-PCR. The level of iNOS protein expression was examined by immunoblotting. Together these data demonstrate that SES treatment lowered the progression of diabetic retinal injury by: 1) decreasing blood glucose level, 2) suppressing microglia activation, 3) reducing retinal TNF-α and ICAM-1 levels and 4) quenching iNOS expression. In conclusion, the results suggest that SES treatment may be of therapeutic benefit in reducing the progression of DR by ameliorating hyperglycemia and inflammation in diabetic retina.

Original languageEnglish (US)
Pages (from-to)47-53
Number of pages7
JournalJournal of Neuroimmunology
Volume295-296
DOIs
StatePublished - Jun 15 2016

Fingerprint

Diabetic Retinopathy
Streptozocin
Anti-Inflammatory Agents
Nitric Oxide Synthase Type II
Microglia
Intercellular Adhesion Molecule-1
Blood Glucose
Retina
Tumor Necrosis Factor-alpha
Sesamum
Inflammation
Therapeutics
Diabetic Angiopathies
sesamin
Blindness
Immunoblotting
Hyperglycemia
Free Radicals
Seeds
Oils

Keywords

  • Anti-inflammation
  • Cytokines
  • Diabetic retinopathy
  • Microglia
  • Sesamin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Cite this

Ahmad, S., ElSherbiny, N. M., Jamal, M. S., Alzahrani, F. A., Haque, R., Khan, R., ... Bhatia, K. (2016). Anti-inflammatory role of sesamin in STZ induced mice model of diabetic retinopathy. Journal of Neuroimmunology, 295-296, 47-53. https://doi.org/10.1016/j.jneuroim.2016.04.002

Anti-inflammatory role of sesamin in STZ induced mice model of diabetic retinopathy. / Ahmad, Saif; ElSherbiny, Nehal M.; Jamal, Mohammad Sarwar; Alzahrani, Faisal A.; Haque, Rizwanul; Khan, Raziuddin; Zaidi, Syed Kashif; AlQahtani, Mohammed H.; Liou, Gregory I; Bhatia, Kanchan.

In: Journal of Neuroimmunology, Vol. 295-296, 15.06.2016, p. 47-53.

Research output: Contribution to journalArticle

Ahmad, S, ElSherbiny, NM, Jamal, MS, Alzahrani, FA, Haque, R, Khan, R, Zaidi, SK, AlQahtani, MH, Liou, GI & Bhatia, K 2016, 'Anti-inflammatory role of sesamin in STZ induced mice model of diabetic retinopathy', Journal of Neuroimmunology, vol. 295-296, pp. 47-53. https://doi.org/10.1016/j.jneuroim.2016.04.002
Ahmad, Saif ; ElSherbiny, Nehal M. ; Jamal, Mohammad Sarwar ; Alzahrani, Faisal A. ; Haque, Rizwanul ; Khan, Raziuddin ; Zaidi, Syed Kashif ; AlQahtani, Mohammed H. ; Liou, Gregory I ; Bhatia, Kanchan. / Anti-inflammatory role of sesamin in STZ induced mice model of diabetic retinopathy. In: Journal of Neuroimmunology. 2016 ; Vol. 295-296. pp. 47-53.
@article{1a7cf58595704ec7a904348d31b21c1d,
title = "Anti-inflammatory role of sesamin in STZ induced mice model of diabetic retinopathy",
abstract = "Diabetic retinopathy (DR) is the common cause of diabetic vascular complications that leads to the blindness in the working age population throughout the world. Free radicals mediated oxidative stress and inflammation play a significant role in pathophysiology of DR. To find a new and safe drug to treat DR is still challenging and for that purpose the natural compounds may be therapeutic agents. Here we show that sesamin (SES) which is the main components of sesame seed and its oil, and has been reported as potent antioxidant and neuroprotective, could be a therapeutic agent in DR. In the present study, we investigated protective effect of SES in Streptozotocin (STZ) induced DR in mice. The mice were divided into three groups (Control, DR and DR+SES) for the study. After two weeks post-diabetic establishment, mice were treated with SES (30 mg/kg BW, i.p, alternate day) for four weeks. Mice body weight and blood glucose level were measured from each group. The microglial activation of retina was determined by immunohistochemistry analysis by using Iba-1 as a microglia marker. Retinal mRNA levels of Iba-1, tumor necrosis factor-α (TNF-α), inducible nitric oxide synthase (iNOS) and Intercellular Adhesion Molecule 1 (ICAM-1) were examined by qRT-PCR. The level of iNOS protein expression was examined by immunoblotting. Together these data demonstrate that SES treatment lowered the progression of diabetic retinal injury by: 1) decreasing blood glucose level, 2) suppressing microglia activation, 3) reducing retinal TNF-α and ICAM-1 levels and 4) quenching iNOS expression. In conclusion, the results suggest that SES treatment may be of therapeutic benefit in reducing the progression of DR by ameliorating hyperglycemia and inflammation in diabetic retina.",
keywords = "Anti-inflammation, Cytokines, Diabetic retinopathy, Microglia, Sesamin",
author = "Saif Ahmad and ElSherbiny, {Nehal M.} and Jamal, {Mohammad Sarwar} and Alzahrani, {Faisal A.} and Rizwanul Haque and Raziuddin Khan and Zaidi, {Syed Kashif} and AlQahtani, {Mohammed H.} and Liou, {Gregory I} and Kanchan Bhatia",
year = "2016",
month = "6",
day = "15",
doi = "10.1016/j.jneuroim.2016.04.002",
language = "English (US)",
volume = "295-296",
pages = "47--53",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",

}

TY - JOUR

T1 - Anti-inflammatory role of sesamin in STZ induced mice model of diabetic retinopathy

AU - Ahmad, Saif

AU - ElSherbiny, Nehal M.

AU - Jamal, Mohammad Sarwar

AU - Alzahrani, Faisal A.

AU - Haque, Rizwanul

AU - Khan, Raziuddin

AU - Zaidi, Syed Kashif

AU - AlQahtani, Mohammed H.

AU - Liou, Gregory I

AU - Bhatia, Kanchan

PY - 2016/6/15

Y1 - 2016/6/15

N2 - Diabetic retinopathy (DR) is the common cause of diabetic vascular complications that leads to the blindness in the working age population throughout the world. Free radicals mediated oxidative stress and inflammation play a significant role in pathophysiology of DR. To find a new and safe drug to treat DR is still challenging and for that purpose the natural compounds may be therapeutic agents. Here we show that sesamin (SES) which is the main components of sesame seed and its oil, and has been reported as potent antioxidant and neuroprotective, could be a therapeutic agent in DR. In the present study, we investigated protective effect of SES in Streptozotocin (STZ) induced DR in mice. The mice were divided into three groups (Control, DR and DR+SES) for the study. After two weeks post-diabetic establishment, mice were treated with SES (30 mg/kg BW, i.p, alternate day) for four weeks. Mice body weight and blood glucose level were measured from each group. The microglial activation of retina was determined by immunohistochemistry analysis by using Iba-1 as a microglia marker. Retinal mRNA levels of Iba-1, tumor necrosis factor-α (TNF-α), inducible nitric oxide synthase (iNOS) and Intercellular Adhesion Molecule 1 (ICAM-1) were examined by qRT-PCR. The level of iNOS protein expression was examined by immunoblotting. Together these data demonstrate that SES treatment lowered the progression of diabetic retinal injury by: 1) decreasing blood glucose level, 2) suppressing microglia activation, 3) reducing retinal TNF-α and ICAM-1 levels and 4) quenching iNOS expression. In conclusion, the results suggest that SES treatment may be of therapeutic benefit in reducing the progression of DR by ameliorating hyperglycemia and inflammation in diabetic retina.

AB - Diabetic retinopathy (DR) is the common cause of diabetic vascular complications that leads to the blindness in the working age population throughout the world. Free radicals mediated oxidative stress and inflammation play a significant role in pathophysiology of DR. To find a new and safe drug to treat DR is still challenging and for that purpose the natural compounds may be therapeutic agents. Here we show that sesamin (SES) which is the main components of sesame seed and its oil, and has been reported as potent antioxidant and neuroprotective, could be a therapeutic agent in DR. In the present study, we investigated protective effect of SES in Streptozotocin (STZ) induced DR in mice. The mice were divided into three groups (Control, DR and DR+SES) for the study. After two weeks post-diabetic establishment, mice were treated with SES (30 mg/kg BW, i.p, alternate day) for four weeks. Mice body weight and blood glucose level were measured from each group. The microglial activation of retina was determined by immunohistochemistry analysis by using Iba-1 as a microglia marker. Retinal mRNA levels of Iba-1, tumor necrosis factor-α (TNF-α), inducible nitric oxide synthase (iNOS) and Intercellular Adhesion Molecule 1 (ICAM-1) were examined by qRT-PCR. The level of iNOS protein expression was examined by immunoblotting. Together these data demonstrate that SES treatment lowered the progression of diabetic retinal injury by: 1) decreasing blood glucose level, 2) suppressing microglia activation, 3) reducing retinal TNF-α and ICAM-1 levels and 4) quenching iNOS expression. In conclusion, the results suggest that SES treatment may be of therapeutic benefit in reducing the progression of DR by ameliorating hyperglycemia and inflammation in diabetic retina.

KW - Anti-inflammation

KW - Cytokines

KW - Diabetic retinopathy

KW - Microglia

KW - Sesamin

UR - http://www.scopus.com/inward/record.url?scp=84964317804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964317804&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2016.04.002

DO - 10.1016/j.jneuroim.2016.04.002

M3 - Article

C2 - 27235348

AN - SCOPUS:84964317804

VL - 295-296

SP - 47

EP - 53

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

ER -